[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354240-105":59,"doc-detail-354240-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","esr1-fusion-proteins-in-breast-cancer-distinguishing-oncogenic-drivers-from-passenger-events","ESR1 fusion proteins in breast cancer - distinguishing oncogenic drivers from passenger events","","Breast cancer shows profound genetic heterogeneity, with ESR1 (oestrogen receptor alpha) acting as a central driver in ~70% of cases. While ESR1 ligand-binding domain point mutations are known to cause endocrine resistance, ESR1 gene fusions have emerged as clinically important alterations. These intrachromosomal 6q events truncate the ligand-binding domain and create constitutively active chimeric proteins with therapy resistance and worse outcomes. The review evaluates determinants of fusion functionality and distinguishes true oncogenic drivers from passenger events to guide diagnostics and therapy development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/esr1-fusion-proteins-in-breast-cancer-distinguishing-oncogenic-drivers-from-passenger-events/354240/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/esr1-fusion-proteins-in-breast-cancer-distinguishing-oncogenic-drivers-from-passenger-events/354240.png","ImageObject",300,407,{"name":92,"@type":93},"Stanford","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are ESR1 gene fusions in breast cancer and how do they differ from ESR1 point mutations?","Question",{"text":112,"@type":113},"ESR1 fusions are genomic rearrangements that truncate the ligand-binding domain and fuse ESR1 with diverse partners, creating ligand-independent chimeric proteins. ESR1 point mutations instead occur within the ligand-binding domain and also drive ligand-independent activity, leading to endocrine resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why are ESR1 fusions considered possible oncogenic drivers rather than passenger events?",{"text":117,"@type":113},"Many recurrent ESR1 fusions are associated with therapy resistance, metastatic progression, and poor clinical outcomes, suggesting functional roles in tumour progression. The review also highlights molecular determinants such as reading-frame preservation and partner-provided domains that support biological activity.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors determine whether an ESR1 fusion is biologically functional?",{"text":121,"@type":113},"Functional fusions depend on features including reading-frame preservation, domain architecture, intrinsic disorder content, and molecular contributions from the partner gene, which often encodes transcription factors, signalling adaptors, or cytoskeletal regulators.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354240,1791098377,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Oncogene [www.nature.com/onc](www.nature.com/onc)  \nREVIEW ARTICLE OPEN   \nESR1 fusion proteins in breast cancer: distinguishing oncogenicdrivers from passenger events  \nAna-Maria Gherghelas 1 ✉ and Christopher P. Toseland 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Breast cancer is characterised by profound genetic heterogeneity, with oestrogen receptor alpha (ERα, encoded by ESR1) being a central driver in ~70% of cases. While point mutations in the ligand-binding domain of ESR1 are well recognised mediators of endocrine resistance, a growing body of evidence highlights ESR1 gene fusions as an emerging class of genomic alterations with important clinical implications. These rearrangements, predominantly arising from intrachromosomal events on chromosome 6, truncate the hormone-binding domain and fuse ESR1 with diverse partners, producing constitutively active chimeric proteins. Recurrent fusions such as ESR1–CCDC170, ESR1–YAP1, and ESR1–AKAP12 have been consistently associated with therapy resistance, metastatic progression, and poor clinical outcome, suggesting that they function as oncogenic drivers rather than incidental by-products of genomic instability. However, variability in oncogenic potential indicates that only a subset of fusions are biologically functional. Key determinants of functionality include reading-frame preservation, domain architecture, intrinsic disorder content, and the molecular features contributed by the partner gene, many of which encode transcription factors, signalling adaptors, or cytoskeletal regulators. Structural enrichment in intrinsically disordered regions and the potential for phase separation further implicate ESR1 fusions in the formation of aberrant transcriptional condensates that amplify ER signalling. Importantly, while many fusions are enriched in metastatic, treatment-resistant disease, a small number are present in treatmentnaïve tumours, raising the possibility that some act as early drivers of oncogenesis. This review outlines the current knowledge on ESR1 fusions, evaluating their mechanisms and clinical relevance. Clarifying which ESR1 fusions act as true oncogenic drivers versus incidental events will be critical for reﬁning diagnostics and informing future therapeutic development for oncofusion- |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| driven cancers. |  |  |\n|  | Oncogene (2026) 45:2075–2084; [https://doi.org/10.1038/s41388-026-03813-w](https://doi.org/10.1038/s41388-026-03813-w) |  |\n|  |  |  |\n\nINTRODUCTION  \nBreast cancer is a highly heterogeneous disease where point mutations and gene ampliﬁcations, are well-characterised drivers of tumour development. Advances in deep sequencing have uncovered novel genomic alterations, including gene fusions that generate hybrid proteins combining domains from distinct partners [1, 2] . The proteins produced by these chimeric transcripts often display altered expression, regulation and/or structure [3, 4], which can affect their original functionality and even introduce novel properties [5] .  \nThe prevalence of gene fusions varies across cancer types, with currently known translocations accounting for ~20% of cases [6] . Whilst extensively studied in haematological malignancies, their presence and pathological implication in solid tumours is poorly understood [6, 7] . However, the number of gene fusions detected in solid tumours has increased in recent years, suggesting that chromosomal events are more prevalent than previously recognised [1, 8] .  \nIn breast cancer, several recurrent gene fusions have been identiﬁed, including ETV6–NTRK3, ERBB2, RET, FGFR, BRAF and MAST rearrangements [9–12] . Among these, ESR1 fusions represent an emerging class of genomic alterations. ESR1 encodes  \noestrogen receptor alpha (ERα), which is expressed in ~70% of breast cancers and drive","cbCaib1KXAvXhmc8","https://ap.wps.com/l/cbCaib1KXAvXhmc8","pdf",1620504,"English","# Introduction\n## Gene fusions in cancer and their prevalence\n## ESR1, ERα signalling, and endocrine resistance\n## ESR1 fusion biology and emerging clinical relevance\n## The challenge of distinguishing drivers from passenger events\n# Conclusions and clinical implications","[{\"question\":\"What are ESR1 gene fusions in breast cancer and how do they differ from ESR1 point mutations?\",\"answer\":\"ESR1 fusions are genomic rearrangements that truncate the ligand-binding domain and fuse ESR1 with diverse partners, creating ligand-independent chimeric proteins. ESR1 point mutations instead occur within the ligand-binding domain and also drive ligand-independent activity, leading to endocrine resistance.\"},{\"question\":\"Why are ESR1 fusions considered possible oncogenic drivers rather than passenger events?\",\"answer\":\"Many recurrent ESR1 fusions are associated with therapy resistance, metastatic progression, and poor clinical outcomes, suggesting functional roles in tumour progression. The review also highlights molecular determinants such as reading-frame preservation and partner-provided domains that support biological activity.\"},{\"question\":\"What factors determine whether an ESR1 fusion is biologically functional?\",\"answer\":\"Functional fusions depend on features including reading-frame preservation, domain architecture, intrinsic disorder content, and molecular contributions from the partner gene, which often encodes transcription factors, signalling adaptors, or cytoskeletal regulators.\"}]","ESR1 fusion proteins in breast cancer - distinguishing oncogenic drivers from passenger events | PDF",1790109705,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/643b6398f1bc99ae79ddf3b58c3c7b4f.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a2b89f4f8b96c4a39ceea520de8c83f.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8dc968ac66cdb225dfa9ed22a3df80c.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5098bb832fa443c9161a560bb735e197.webp",980,1301]